JP2002501526A - 乳汁における免疫グロブリンａの生成方法 - Google Patents
乳汁における免疫グロブリンａの生成方法Info
- Publication number
- JP2002501526A JP2002501526A JP50054699A JP50054699A JP2002501526A JP 2002501526 A JP2002501526 A JP 2002501526A JP 50054699 A JP50054699 A JP 50054699A JP 50054699 A JP50054699 A JP 50054699A JP 2002501526 A JP2002501526 A JP 2002501526A
- Authority
- JP
- Japan
- Prior art keywords
- iga
- antigen
- milk
- imm
- immunization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229940099472 immunoglobulin a Drugs 0.000 title claims abstract description 137
- 239000008267 milk Substances 0.000 title claims description 90
- 210000004080 milk Anatomy 0.000 title claims description 90
- 235000013336 milk Nutrition 0.000 title claims description 89
- 238000004519 manufacturing process Methods 0.000 title claims description 21
- 238000002649 immunization Methods 0.000 claims abstract description 113
- 230000003053 immunization Effects 0.000 claims abstract description 109
- 238000000034 method Methods 0.000 claims abstract description 102
- 108091007433 antigens Proteins 0.000 claims abstract description 90
- 102000036639 antigens Human genes 0.000 claims abstract description 90
- 239000000427 antigen Substances 0.000 claims abstract description 85
- 238000007912 intraperitoneal administration Methods 0.000 claims abstract description 75
- 238000007918 intramuscular administration Methods 0.000 claims abstract description 72
- 230000001939 inductive effect Effects 0.000 claims abstract description 9
- 241001465754 Metazoa Species 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 33
- 241000124008 Mammalia Species 0.000 claims description 27
- 239000002671 adjuvant Substances 0.000 claims description 25
- 230000035606 childbirth Effects 0.000 claims description 16
- 241000283707 Capra Species 0.000 claims description 14
- 241000283690 Bos taurus Species 0.000 claims description 13
- 241000588724 Escherichia coli Species 0.000 claims description 12
- 235000015872 dietary supplement Nutrition 0.000 claims description 9
- 230000003115 biocidal effect Effects 0.000 claims description 8
- 241001494479 Pecora Species 0.000 claims description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 241000222122 Candida albicans Species 0.000 claims description 5
- 241000711573 Coronaviridae Species 0.000 claims description 5
- 241000204031 Mycoplasma Species 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000032696 parturition Effects 0.000 claims description 5
- 241000702670 Rotavirus Species 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 239000002537 cosmetic Substances 0.000 claims description 4
- 235000013365 dairy product Nutrition 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 241000191940 Staphylococcus Species 0.000 claims description 3
- 241000194017 Streptococcus Species 0.000 claims description 3
- 229940095731 candida albicans Drugs 0.000 claims description 3
- 239000000428 dust Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 241000588832 Bordetella pertussis Species 0.000 claims description 2
- 102000009016 Cholera Toxin Human genes 0.000 claims description 2
- 108010049048 Cholera Toxin Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 241000588722 Escherichia Species 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 241000607768 Shigella Species 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229930182490 saponin Natural products 0.000 claims description 2
- 150000007949 saponins Chemical class 0.000 claims description 2
- 235000017709 saponins Nutrition 0.000 claims description 2
- 230000003252 repetitive effect Effects 0.000 claims 3
- 241000589876 Campylobacter Species 0.000 claims 1
- 241000589989 Helicobacter Species 0.000 claims 1
- 241000282342 Martes americana Species 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 102000003390 tumor necrosis factor Human genes 0.000 claims 1
- 210000005075 mammary gland Anatomy 0.000 description 52
- 230000004044 response Effects 0.000 description 32
- 238000009472 formulation Methods 0.000 description 29
- 239000000523 sample Substances 0.000 description 22
- 230000002163 immunogen Effects 0.000 description 19
- 108060003951 Immunoglobulin Proteins 0.000 description 17
- 102000018358 immunoglobulin Human genes 0.000 description 17
- 229960005486 vaccine Drugs 0.000 description 14
- 230000006651 lactation Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 11
- 241000282849 Ruminantia Species 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 235000021277 colostrum Nutrition 0.000 description 10
- 210000003022 colostrum Anatomy 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 230000036039 immunity Effects 0.000 description 9
- 206010070834 Sensitisation Diseases 0.000 description 8
- 229940072221 immunoglobulins Drugs 0.000 description 8
- 230000008313 sensitization Effects 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 239000012266 salt solution Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000004907 gland Anatomy 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012286 ELISA Assay Methods 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 235000020256 human milk Nutrition 0.000 description 4
- 210000004251 human milk Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 206010067482 No adverse event Diseases 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 239000000417 fungicide Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000002917 insecticide Substances 0.000 description 3
- 208000004396 mastitis Diseases 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 241000702673 Bovine rotavirus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010022678 Intestinal infections Diseases 0.000 description 2
- 231100000678 Mycotoxin Toxicity 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 231100000742 Plant toxin Toxicity 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000020243 first infant milk formula Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000005428 food component Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 239000004009 herbicide Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002636 mycotoxin Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000003123 plant toxin Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 208000018556 stomach disease Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 241000223936 Cryptosporidium parvum Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 102000010029 Homer Scaffolding Proteins Human genes 0.000 description 1
- 108010077223 Homer Scaffolding Proteins Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 241001496375 Iris albicans Species 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- 101100046537 Ovis aries TNF gene Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 210000000026 apposition eye Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000002013 dioxins Chemical class 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 244000000075 gastric pathogen Species 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000013062 quality control Sample Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000014268 sports nutrition Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/04—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ31495997 | 1997-05-29 | ||
| NZ314959 | 1997-05-29 | ||
| PCT/NZ1998/000070 WO1998054226A1 (en) | 1997-05-29 | 1998-05-29 | Processes for production of immunoglobulin a in milk |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002501526A true JP2002501526A (ja) | 2002-01-15 |
| JP2002501526A5 JP2002501526A5 (enExample) | 2005-12-08 |
Family
ID=19926267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50054699A Ceased JP2002501526A (ja) | 1997-05-29 | 1998-05-29 | 乳汁における免疫グロブリンａの生成方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US6616927B2 (enExample) |
| EP (1) | EP0990001B1 (enExample) |
| JP (1) | JP2002501526A (enExample) |
| AT (1) | ATE325817T1 (enExample) |
| AU (1) | AU738888B2 (enExample) |
| BR (1) | BR9809186A (enExample) |
| CA (1) | CA2291487A1 (enExample) |
| DE (1) | DE69834490T2 (enExample) |
| WO (1) | WO1998054226A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012250984A (ja) * | 2005-10-21 | 2012-12-20 | Gtc Biotherapeutics Inc | 抗体依存性細胞障害活性を増強させた抗体、その調製法および使用法 |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ15898A3 (cs) * | 1998-01-19 | 1999-11-17 | Medipharm Cz, S. R. O. | Perorální přípravek k prevenci a léčbě infekčních gastroenteritid telat |
| US20020009429A1 (en) * | 1999-01-29 | 2002-01-24 | Galagen, Inc. | Pharmaceutical composition comprising a selected antigen and candida species antigen and methods |
| ES2258483T3 (es) * | 1999-11-01 | 2006-09-01 | Mucovax Holding B.V | Produccion de anticuerpos de secrecion mamaria en animales de granja. |
| US7074454B1 (en) | 1999-11-01 | 2006-07-11 | Mucovax Holding B.V. | Production of mammary secretion antibodies in farm animals |
| US6974573B2 (en) * | 1999-11-01 | 2005-12-13 | Mucovax Holdings, B.V. | Antibody production in farm animals |
| AU2002239159A1 (en) * | 2001-03-12 | 2002-09-24 | Rijksuniversiteit Groningen | Modulation of a balance between the gut mucosal immune system and the intestinal microflora |
| WO2003055502A1 (en) * | 2001-12-24 | 2003-07-10 | Fonterra Co-Operative Group Limited | Immunoglobulin composition |
| ES2544477T3 (es) | 2003-10-03 | 2015-08-31 | 3M Innovative Properties Company | Imidazoquinolinas sustituidas con alcoxi |
| FI116904B (fi) * | 2003-10-21 | 2006-03-31 | Suomen Rehu Oy | Menetelmä maidon koostumuksen muuttamiseksi ja maidon käyttö |
| US20070065518A1 (en) * | 2003-10-22 | 2007-03-22 | Harry Leneau | Colostrum compositions and methods |
| FR2861306B1 (fr) * | 2003-10-28 | 2008-07-04 | Vivafeed | Utilisation du shiitake pour augmenter le taux d'immunoglobulines laitieres |
| RU2409576C2 (ru) | 2003-11-25 | 2011-01-20 | 3М Инновейтив Пропертиз Компани | Системы, содержащие имидазольное кольцо с заместителями, и способы их получения |
| NZ530709A (en) * | 2004-01-21 | 2006-07-28 | Agres Ltd | Improved IGA production method |
| JP2008526752A (ja) * | 2004-12-30 | 2008-07-24 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫応答調節剤化合物の多経路投与 |
| US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
| EP1879908B1 (en) * | 2005-05-10 | 2014-01-08 | Murray Goulburn Co-Operative Co Limited | Immunoglobulin fraction and process therefor |
| US20100303830A1 (en) * | 2007-12-11 | 2010-12-02 | Nestec S.A. | PREVENTION AND TREATMENT OF OTITIS MEDIA USING IgA ENRICHED MILK |
| EP2138187A1 (en) * | 2008-06-24 | 2009-12-30 | Nestec S.A. | Probiotics, secretory IgA and infection |
| WO2010050829A1 (en) * | 2008-10-31 | 2010-05-06 | Vialactia Biosciences (Nz) Limited | Marker assisted selection of a mammalian subject for desired immunoglobulin phenotype |
| PH12013501040A1 (en) | 2010-11-23 | 2022-10-24 | Pantheryx Inc | Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications |
| BR112015019341A2 (pt) | 2013-02-13 | 2017-08-22 | Lab Francais Du Fractionnement | Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal |
| EP2956003A2 (en) | 2013-02-13 | 2015-12-23 | Laboratoire Français du Fractionnement et des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
| US12263192B2 (en) | 2019-02-26 | 2025-04-01 | Pantheryx, Inc. | Compositions for management of disorders of the gastrointestinal tract |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH627079A5 (en) * | 1977-04-15 | 1981-12-31 | Nestle Sa | Process for preparing a protein concentrate containing immunological factors of milk origin |
| US4229342A (en) | 1977-05-18 | 1980-10-21 | Rhone-Poulenc Industries | Process for extracting proteins from milk using silica and anion exchange resins |
| FR2520235A1 (fr) | 1982-01-27 | 1983-07-29 | Bel Fromageries | Procede de separation d'immunoglobulines a partir de colostrum |
| US4971794A (en) * | 1982-09-02 | 1990-11-20 | Unilever Patent Holdings B.V. | Production of antibodies using a mixture of strains of E. coli collectively expressing type I pili, CFA I pili, CFA II pili and K88 pili |
| DE3432718C1 (de) | 1984-09-06 | 1986-05-22 | Biotest Pharma GmbH, 6000 Frankfurt | Verfahren zur Herstellung einer Loesung von Milch- und/oder Kolostralimmunglobulinen |
| US5066491A (en) | 1985-04-15 | 1991-11-19 | Protein Technology, Inc. | Method of disease treatment utilizing an immunologically active whey fraction |
| FR2584727B1 (fr) | 1985-07-11 | 1988-06-17 | Roussel Uclaf | Procede d'extraction de proteines du lait, produits, application du procede, et compositions pharmaceutiques |
| US5013824A (en) * | 1985-11-19 | 1991-05-07 | Schering Corporation | Human interleukin-4 peptides and conjugates thereof |
| US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| GB8729031D0 (en) | 1987-12-11 | 1988-01-27 | Express Foods Group Ltd | Isolation of immunoglobulin rich fraction from whey |
| US5001230A (en) * | 1988-02-18 | 1991-03-19 | Schering Corporation | T cell activation markers |
| US5258178A (en) | 1990-07-30 | 1993-11-02 | Abbott Laboratories | Method and product for the treatment of gastric disease |
| IE76730B1 (en) | 1990-07-30 | 1997-11-05 | Abbott Laboraties | Method and product for the treatment of gastric disease |
| NZ239466A (en) | 1990-08-17 | 1993-12-23 | Us Agriculture | Desalted colostrum: spray dried product from retentate of |
| US5418137A (en) * | 1991-09-26 | 1995-05-23 | Paravax, Inc. | Flea membrane binding site proteins as screening tools |
| US5155213A (en) * | 1991-10-28 | 1992-10-13 | Eloy Padron | Method for isolating IgAs in the feces |
| US5650173A (en) * | 1993-11-19 | 1997-07-22 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
| US6592905B1 (en) | 1996-01-31 | 2003-07-15 | Massey University | Production of an immunoglobulin enriched fraction from whey protein solutions |
-
1998
- 1998-05-29 DE DE1998634490 patent/DE69834490T2/de not_active Expired - Fee Related
- 1998-05-29 EP EP98929914A patent/EP0990001B1/en not_active Expired - Lifetime
- 1998-05-29 US US09/424,246 patent/US6616927B2/en not_active Expired - Lifetime
- 1998-05-29 WO PCT/NZ1998/000070 patent/WO1998054226A1/en not_active Ceased
- 1998-05-29 CA CA 2291487 patent/CA2291487A1/en not_active Abandoned
- 1998-05-29 JP JP50054699A patent/JP2002501526A/ja not_active Ceased
- 1998-05-29 AT AT98929914T patent/ATE325817T1/de not_active IP Right Cessation
- 1998-05-29 AU AU79420/98A patent/AU738888B2/en not_active Expired
- 1998-05-29 BR BR9809186A patent/BR9809186A/pt not_active Application Discontinuation
-
2002
- 2002-02-08 US US10/067,870 patent/US20030074676A1/en not_active Abandoned
- 2002-02-08 US US10/067,792 patent/US20030103989A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012250984A (ja) * | 2005-10-21 | 2012-12-20 | Gtc Biotherapeutics Inc | 抗体依存性細胞障害活性を増強させた抗体、その調製法および使用法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20030103989A1 (en) | 2003-06-05 |
| US20020076410A1 (en) | 2002-06-20 |
| BR9809186A (pt) | 2000-08-01 |
| US6616927B2 (en) | 2003-09-09 |
| EP0990001A1 (en) | 2000-04-05 |
| CA2291487A1 (en) | 1998-12-03 |
| DE69834490T2 (de) | 2007-03-01 |
| EP0990001B1 (en) | 2006-05-10 |
| AU738888B2 (en) | 2001-09-27 |
| AU7942098A (en) | 1998-12-30 |
| EP0990001A4 (en) | 2004-08-25 |
| DE69834490D1 (de) | 2006-06-14 |
| ATE325817T1 (de) | 2006-06-15 |
| WO1998054226A1 (en) | 1998-12-03 |
| US20030074676A1 (en) | 2003-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002501526A (ja) | 乳汁における免疫グロブリンａの生成方法 | |
| CA2260007C (en) | Method for treating gastrointestinal damage | |
| US5585098A (en) | Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants | |
| US5017372A (en) | Method of producing antibody-fortified dry whey | |
| JPH08231425A (ja) | トリの抗体を用いた哺乳動物の受動免疫化 | |
| WO1997020577A1 (en) | Improved therapeutic formulation and method | |
| US20070141079A1 (en) | Antibody production in farm animals | |
| US20020009429A1 (en) | Pharmaceutical composition comprising a selected antigen and candida species antigen and methods | |
| US4971794A (en) | Production of antibodies using a mixture of strains of E. coli collectively expressing type I pili, CFA I pili, CFA II pili and K88 pili | |
| JPS62215534A (ja) | 鶏卵からの特異的抗体含有材料およびその製造方法と用途 | |
| EP0484148A1 (en) | A method for producing a new medicine for both treating and preventing peptic ulcer diseases and gastritis and thus formulated medicines | |
| JPH02160726A (ja) | ワクチン | |
| WO1999002188A1 (en) | Hen egg yolk antibodies to clostridium difficile antigens and use in therapy for pseudomembranous colitis | |
| CA2233935A1 (en) | Process for isolating immunoglobulins in whey | |
| Xu et al. | Bovine immune colostrum against 17 strains of diarrhea bacteria and in vitro and in vivo effects of its specific IgG | |
| RU2062109C1 (ru) | Способ получения иммунного препарата | |
| KR100627635B1 (ko) | 가축에서 유선 분비 항체를 제조하는 방법 | |
| WO2005070458A1 (en) | Improved iga production method | |
| US10478493B2 (en) | Method of treating protozoal gastrointestinal disorders in immunocompromised patients | |
| NZ501247A (en) | Processes for production of immunoglobulin A in milk comprising inducing IgA via active immunisation with intramammary, intraperitoneal and intramuscular administration. | |
| MXPA99010944A (en) | Processes for production of immunoglobulin a in milk | |
| JPH05306238A (ja) | 特異的抗体及びカイコ感染症防除組成物 | |
| JP2001011094A (ja) | 乳ホエ−タンパク中の生理活性物質およびその製造法ならびにその使用法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050525 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050525 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080520 |
|
| A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20081014 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081202 |